Novavax "COVID-19 Vaccine Effectiveness 96.4%"

Phase 3 Clinical Results... 86% Against UK Variant, 55% Against South Africa Variant

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Kim Suhwan] The COVID-19 vaccine developed by the U.S. pharmaceutical company Novavax has been found to have a preventive efficacy of 96.4%.

Novavax announced this on the 11th (local time) when releasing the results of its Phase 3 clinical trial conducted in the United Kingdom. The efficacy in preventing severe cases was found to be 100%.

It showed 86% preventive efficacy against the variant originating from the UK. However, the efficacy against the variant from the Republic of South Africa (Nam-Africa) was only 55%.

The Phase 3 clinical trial results are similar to the interim announcement made in January. At that time, Novavax stated that its vaccine showed preventive efficacy of 96% against COVID-19 and 86% against the UK variant, respectively.

Based on the Phase 3 clinical trial results, Novavax plans to apply for approval in various countries, including the United States. Regarding the application to the U.S. Food and Drug Administration (FDA), major foreign media reported, "Since the U.S. may require completion of domestic clinical trials, it is uncertain when Novavax will apply to the FDA."

This content was produced with the assistance of AI translation services.